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Abstract 
Background: We identified pain variation according to prostate biopsy sites and compared differences in pain relief 
according to the site of periprostatic nerve block (PNB).
Methods: This retrospective study collected data from 312 patients who underwent transrectal prostate biopsies 
between January 2019 and August 2020. Patients were stratified into two groups according to the site of local anes-
thesia (base vs. base and apex PNB), with each block achieved with 2.5  cm3 of 2% lidocaine. Pain scores were assessed 
using the visual analog scale at the following time points: probe insertion, PNB at base, PNB at apex, each of the 12 
core biopsy sites, and 15 min after biopsy. The results were analyzed using a linear mixed model.
Results: The average pain scores were significantly higher in the base-only PNB group than were those in the base 
and apex PNB group (3.88 vs 2.82, p < 0.001). In the base-only PNB group, the pain scores increased from base to apex 
(p < 0.001), and the pain at each site also gradually increased as the biopsy proceeded (p < 0.001). In contrast, in the 
base and apex PNB group, there was minor change in pain scores throughout the procedure.
Conclusions: The pain scores varied at each site during the prostate biopsy. The provision of a base and apex PNB 
provided greater pain relief than does base-only PNB during prostate biopsy.
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Background
Systematic random prostate biopsy is generally per-
formed via a transrectal or transperineal approach for the 
diagnosis of prostate cancer [1, 2]. The transrectal ultra-
sound (TRUS)-guided random prostate biopsy may cause 
severe pain, hematuria, urinary retention, infection, and 
even septic shock [3–5]. As the experience of pain dur-
ing prostate biopsy lowers patient compliance, this pro-
cedure should be performed under local anesthesia, in 
accordance with the guidelines provided by the National 
Comprehensive Cancer Network (NCCN).
The availability of various anesthetic techniques greatly 
enhances patients’ acceptability of prostate biopsy. Active 
pain relief was not previously adopted; however, for 
pain relief, general anesthesia, intrarectal local anesthe-
sia, pudendal and caudal nerve block, periprostatic local 
anesthesia, intravenous conscious sedation (propofol, 
midazolam), and intravenous analgesics (fentanyl) have 
been attempted [6]. Among these, intrarectal lidocaine 
gel (IRLG), pelvic plexus block (PPB), and periprostatic 
nerve block (PNB) using prilocaine or lidocaine are gen-
erally used in the clinical setting [7–11].
A previous meta-analysis reported the usefulness of 
both the PPB and PNB for pain relief during prostate 
biopsy, while a recent randomized clinical trial conducted 
by our research group found no difference between the 
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efficacy of the PPB and base PNB [6, 8]. However, in the 
latter study, the PNB was stratified according to the nerve 
block site. The administration of a base PNB and an addi-
tional apex PNB relieve overall pain as it blocks a sensi-
tive somatic nerve branch of the pudendal nerve [12].
With the consideration that the level of pain differs 
according to the site at which the PNB is administered, 
we speculated that pain levels would also differ among 
random biopsy sites, and that the degree of pain relief 
would vary at each site following the administration of 
an additional nerve block. To the best of our knowledge, 
no prior studies have investigated these issues. Therefore, 
we aimed to evaluate differences in pain levels among 12 
core biopsy sites, and assess pain relief according to the 
site of PNB administration.
Methods
Patient selection
This retrospective study collected data from 312 con-
secutive patients who underwent TRUS-guided prostate 
biopsies at single institution (Gangnam Severance Hos-
pital, Yonsei University Health System) between Janu-
ary 2019 and August 2020. The indication for prostate 
biopsy was persistent clinical suspicion of prostate cancer 
due to an elevated prostate-specific antigen (PSA) level 
(> 2.5 ng/mL) and/or a positive digital rectal examination 
(DRE) and continuous rise in PSA level during the follow-
up period. The exclusion criteria comprised the follow-
ing: (1) hemorrhoid grade ≥ III (n = 3), which indicated 
that the hemorrhoid tissue prolapsed beyond the den-
tate line; (2) history of hemorrhoidectomy (n = 1); and 
(3) inability to communicate (n = 4; two were foreigners 
and two were old men with communication difficulties). 
None of the 312 patients had neurological disease such as 
paraplegia or hemiplegia and none routinely used anal-
gesics for chronic pain or other reasons. Finally, a total 
of 304 (97.4%) patients were included in the analysis 
(Fig. 1).  This study was approved by the institutional eth-
ics committee (Yonsei University Health System, Seoul, 
Korea, 3-2019-0418), and all procedures were conducted 
in accordance with the ethical standards of the 1964 Hel-
sinki declaration and its later amendments.  The require-
ment for informed consent was waived for this study as it 
was based on retrospective, anonymous patient data and 
did not involve patient intervention or the use of human 
tissue samples.
Data collection
The collected patient data included age, PSA level, 
prostate volume, history of prostate biopsy, DRE (posi-
tive; hard surface, nodular lesions or mass-like lesion), 
pathologic results, time of PNB and biopsies, adverse 
events (vasovagal syncope, allergic reaction, acute urine 
retention, clot retention, fever), and visual analog scale 
(VAS; ranging from 0 [no pain] to 10 [worst pain]) score 
measured at various time points: probe insertion, PNB at 
base, PNB at apex, each of the 12 core biopsy sites, and 
15 min after prostate biopsy.
TRUS‑guided prostate biopsy technique
All patients were hospitalized for half a day. Antibiot-
ics (third generation cephalosporin) were administered 
prophylactically via intravenous injection 1 h before the 
biopsy and upon discharge (100 mg orally, three times a 
day for 2 days).
The patients assumed a left lateral decubitus position 
during the biopsy. All biopsies were performed by the 
same experienced urologist. After povidone iodine rec-
tal preparation, all patients received 10  cm3 of 2 % IRLG 
(Instillagel®, Farco-Farma GmbH, Köln, Germany). After 
5  min, a transrectal probe was inserted to measure the 
prostate volume, and the PNB procedure was performed 
with a Chiba needle (A & A M.D. Inc., Seongnam, Korea).
Biopsies were performed with the BK 3000 ultrasound 
system (Analogic Corporation, Peabody, MA, USA) 
using a 7.5–12-MHz multiplanar probe at each of the 
12 biopsy sites, in the following order: right lateral base, 
right lateral mid, right lateral apex, right medial base, 
right medial mid, right medial apex, left lateral base, left 
lateral mid, left lateral apex, left medial base, left medial 
mid, and left medial apex. A 20-cm, 18-gauge disposable 
core biopsy instrument (Max-Core®, CR Bard Inc., Cov-
ington, GA, USA) was used in all cases.
Site of injection
The two methods of local anesthesia (base PNB and base 
and apex PNB) were alternately administered—(1) odd 
days (base-only PNB group: the PNB was administered 
on both sides of the prostate base) and (2) even days (base 
and apex PNB group: an additional PNB was adminis-
tered on both sides of the prostate apex). The site of base 
injections was aimed at the major neurovascular bundle, 
after confirming the triangular echogenic “Mount Everest 
sign” between the base of the prostate and seminal vesi-
cle in the parasagittal longitudinal view of the TRUS [6]. 
PNB administration at this site was considered to have 
anesthetized a large portion of the prostate gland. The 
site for apex injections was aimed at a smaller triangular 
echogenicity between the puborectalis muscles and the 
apex of the prostate gland. Each PNB injection utilized 
2.5  cm3 of 2% lidocaine [6]. The base and apex PNB group 
received the base injection before the apex injection.
Study endpoints
The primary study endpoint was the pain scale score for 
the two PNB methods in each of the 12 core biopsy sites. 
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The secondary endpoint was the comparison of pain 
scores between the PNB methods.
Statistical analysis
VAS pain scores in the base and apex PNB were defined 
as the average of the VAS scores for base and apex injec-
tions, respectively. Average pain was defined as the mean 
(± standard deviation [SD]) of the individual VAS pain 
scores at the 12 sites. Average pain at the base, mid, and 
apex of the prostate was defined as the mean (± SD) of 
the individual VAS pain scores at the base, mid, apex 
sites, respectively.
Continuous variables are expressed as either the 
mean ± SD or median (interquartile range). Categorical 
variables were reported as the number of occurrences 
and frequency. Comparisons between the base-only PNB 
group and the base and apex PNB group were performed 
with the independent t-test for continuous variables, and 
the chi-square test (Fisher’s exact test) for two or more 
variables. The results were also analyzed using a linear 
mixed model and illustrated with a mean profile graph. 
The correlation matrix structure of the linear mixed 
model was used to determine the relationship between 
the measured data at various points in time via the appli-
cation of compound symmetry. Statistical analyses were 
performed using SAS (version 9.4.; SAS Institute, Cary, 
NC, USA) and PASS (version 15; NCSS, LLC. Kaysville, 
Utah, USA). The level of statistical significance was set at 
p < 0.05.
Results
Baseline characteristics and VAS pain scores according 
to PNB sites
Patient characteristics and VAS pain scores according 
to PNB sites are presented in Table 1. No differences in 
PSA concentrations (7.56 ng/mL vs. 6.76 ng/mL), pros-
tate volume (36.55 mL vs. 36.79 mL), or prostate cancer 
detection rate (62.9 % vs. 62.1 %) were observed between 




- Hemorrhoid grade ≥ III (n = 3)
- History of hemorrhoidectomy (n = 1)
- Could not communicate (n = 4)
- No patients had neurological disease





The base & apex PNB 
(n = 153)
Fig. 1 Study cohort flow diagram. PNB, periprostatic nerve block; TRUS, transrectal ultrasound
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the base-only PNB group and the base and apex PNB 
group. There were no significant differences in VAS pain 
scores among the different time points (probe insertion, 
PNB at base, and 15 min after prostate biopsy). Average 
pain scores at the base, mid, and apex sites are presented 
in Table 2. The average VAS pain score across all regions 
(overall, base, mid, and apex) in the base and apex PNB 
group was lower than that in the base-only PNB group.
Mean profile plots
Older age (p = 0.029) and higher VAS scores at probe 
insertion (p = 0.002) were correlated with higher indi-
vidual VAS scores in each of the 12 core biopsy sites, 
but a history of prostate biopsy (p = 0.616) and DRE 
(p = 0.131) were not. The mean profile plots show the 
results before and after adjustment for age and VAS pain 
scores at probe insertion; the VAS pain scores for each 
of the 12 core biopsies were not significantly different 
pre- and post-correction for these confounding variables 
(Fig. 2). The VAS pain scores were significantly higher in 
the base-only PNB group than in the base and apex PNB 
group (p < 0.001; Fig.  2). A comparison across biopsy 
locations in the base-only PNB group (after categoriza-
tion of the 12 sites into the base, mid, and apex regions) 
indicated that VAS pain scores increased from the base 
to apex (p < 0.001; Fig. 3). The biopsy of the medial sites 
Table 1 Baseline characteristics and VAS pain scores according to the PNB sites
Data are expressed as number (%), mean ± standard deviation, and median (IQR range)
AUR, acute urinary retention; DRE, digital rectal exam; IQR, interquartile; PNB, periprostatic nerve block; PSA, prostate specific antigen; VAS, visual analog scale
Base Base and apex p
N 151 (49.7) 153 (50.3)
Age (years) 67.86 ± 15.74 68.19 ± 8.59 0.740
PSA (ng/mL) 7.56 (5.40–11.59) 6.76 (4.47–10.19) 0.074
Prostate volume (mL) 36.55 ± 15.74 36.79 ± 16.78 0.900
History of prostate biopsy (n, %) 27 (17.9) 19 (12.4) 0.186
Positive DRE (n, %) 35 (35.7) 25 (28.4) 0.287
Prostate cancer detection rate (n, %) 95 (62.9) 95 (62.1) 0.882
Gleason score 0.171
6 (n, %) 18 (18.9) 26 (27.4)
≥ 7 (n, %) 77 (81.1) 69 (72.6)
Pain
Probe insertion 3.39 ± 2.12 3.36 ± 2.43 0.905
PNB at base 2.91 ± 1.83 2.79 ± 1.94 0.591
PNB at apex 4.60 ± 2.50
At 15 min post prostate biopsy 0.14 ± 0.58 0.16 ± 0.74 0.749
Time
Periprostatic nerve block (min) 2.42 ± 0.77 2.59 ± 0.88 0.084
Prostate biopsy (min) 4.20 ± 2.59 4.66 ± 5.41 0.343
Adverse events
Vasovagal syncope (n, %) 2 (1.3) 0 (0.0) 0.246
Allergic reaction (n, %) 0 (0.0) 0 (0.0) –
AUR (n, %) 0 (0.0) 0 (0.0) –
Urinary retention because of blood clot (n, %) 0 (0.0) 0 (0.0) –
Fever (n, %) 0 (0.0) 0 (0.0) –
Table 2 Mean VAS pain scores in TRUS-guided random prostate 
biopsy groups according to PNB sites
Data are expressed as mean ± standard deviation
PNB, periprostatic nerve block; SD, standard deviation; TRUS, transrectal 
ultrasound; VAS, visual analog scale
a Mean and SD of the average of 12 sites for each individual VAS pain scores
b Mean and SD of the average of 4 base sites for each individual VAS pain scores
c Mean and SD of the average of 4 mid sites for each individual VAS pain scores
d Mean and SD of the average of 4 apex sites for each individual VAS pain scores
Base Base and apex p
12 core VAS pain scores
Average  paina 3.88 ± 2.27 2.82 ± 2.17 < 0.001
Average pain at  baseb 3.74 ± 2.27 2.81 ± 2.20 < 0.001
Average pain at  midc 3.82 ± 2.29 2.81 ± 2.17 < 0.001
Average pain at  apexd 4.08 ± 2.32 2.83 ± 2.18 < 0.001
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was marginally, but significantly, more painful than that 
of the lateral sites within the base region in the base-
only PNB group (p = 0.091); no significant differences 
were observed between the medial and lateral sites in the 
mid (p = 0.134) or apex (p = 0.392) regions. Pain scores 
at each site also gradually increased as the biopsy pro-


















Base and Apex Base
a. Pre-corrected mean profile plot b. Post-corrected mean profile plot
Fig. 2 Mean profile plot of VAS pain scores for each of the 12 core biopsy sites. a VAS pain score before adjustment for age and VAS pain score at 
probe insertion. b VAS pain score after adjustment for age and VAS pain score at probe insertion. Lat, lateral; Lt, left; Med, medial; Rt, right; TRUS, 







Fig. 3 Mean profile plot of VAS pain scores in base, mid, and apex regions. VAS pain scores for each of the 12 core biopsy sites were divided into 
base, mid, and apex regions. Adjustments were made for age and the VAS pain score at probe insertion. Lat, lateral; Lt, left; Med, medial; Rt, right; 
TRUS, transrectal ultrasound; VAS, visual analog scale
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Complications
There were two cases (1.3 %) of vasovagal syncope in 
the base-only PNB group, and both the cases recovered 
without medical therapy. No major complications were 
observed in the base and apex PNB group (Table 1).
Discussion
The main factors related to pain during prostate biopsy 
were identified as age, procedure duration, prostate vol-
ume, and lithotomy position [6, 13–15]. Our results 
confirmed that age and procedure duration are associ-
ated with pain due to TRUS-guided prostate biopsy. The 
administration of a base PNB in addition to an apex PNB 
resulted in lower VAS pain scores when compared to the 
base-only PNB, and this result is consistent with that 
reported in previous studies [6]. We compared VAS pain 
scores for the base-only PNB across the 12 individual 
core biopsy sites and observed higher levels of pain at the 
medial and apex sites than at the lateral and base sites. 
This novel finding suggests that a potential strategy for 
the mitigation of severe pain during the biopsy procedure 
is the administration of an apex PNB, in addition to the 
base PNB.
The conventional method for pain control during a 
TRUS-guided prostate biopsy consists of the combina-
tion of a PNB and IRLG. A meta-analysis of 26 articles 
(comprising 36 randomized controlled trials) concluded 
that the combination of IRLG and PNB is effective and 
safe [16]. The PNB achieves different degrees of pain 
control depending on the lidocaine injection site. Previ-
ous studies have reported the VAS pain score collected 
after the procedure to range between 3.37 and 4.97 for 
the base-only PNB [9, 17, 18]. The VAS pain score of 3.88, 
as observed in our study, was the mean value of scores 
collected at each 12 core biopsy sites and was consistent 
with previously reported values.
The prostate apex is known to be a particularly pain-
ful site in TRUS-guided prostate biopsies because of the 
dominant somatic nerve supply to the region below the 
dentate line [6]. Our results indicated that the apex PNB 
was more painful than the prostate base PNB. The apex 
injection blocks the sensitive somatic nerve branch of the 
inferior rectal nerve (arising from the pudendal nerve), 
which is contained in the distal part of the dentate line; 
this region is penetrated by the needle during PNB or 
biopsy [19]. Thus, the anatomy of this region may explain 
the results of a prior study, which reported the increased 
efficacy of an additional apex lidocaine injection for the 
PNB method [6]. This previous study reported that the 
administration of both a base and apex PNB reduced 
the overall VAS pain score, which is consistent with our 
results.
Rafael et al. reported that pain in each core biopsy site 
became more severe as the procedure proceeded [14]. 
The patients experienced pain when the first puncture 
was performed, which made them more nervous. This, 
in turn, resulted in their tendency to physically avoid the 
pain upon expectation of an ensuing puncture, which 
potentially led to more severe pain during the subse-
quent core biopsy [6, 20]. In our study, the base-only PNB 
group showed similar results. Interestingly, a correlation 
between procedure progression and VAS pain scores was 
not observed in the base and apex PNB group. Thus, our 
results demonstrate the potential benefit of the base and 
apex PNB, in terms of pain control over the duration of 
the biopsy procedure.
The results of the present study indicated that the 
degree of pain relief was also dependent on the site of 
the lidocaine injection. In the base-only PNB group, the 
VAS pain score during the apex biopsy was higher than 
that during the base biopsy. When VAS pain scores were 
compared between the lateral and medial sites, a margin-
ally significant difference was observed only during the 
base biopsy. Since the prostatic base is broader than the 
apex, it can be inferred that a greater distance between 
the biopsy location and lidocaine injection site is asso-
ciated with increased pain for the base-only PNB. Our 
results are consistent with those reported by previous 
studies that investigated the relationship between pros-
tate volume and the efficacy of local anesthesia [15, 16].
The most recent NCCN guidelines have recommended 
that prostate magnetic resonance imaging (MRI) should 
be performed before biopsy to reduce unnecessary pros-
tate biopsies based on the efficacy of radiologic diagno-
sis [21–24]. Prostate MRI is often effective in identifying 
cancerous lesions at the anterior and apex sites, which 
are usually not supported in random prostate biopsies 
[25]. However, the optimal local anesthetic methods 
for MRI-/TRUS-guided biopsy in the anterior and apex 
sites are unknown due to the lack of previous studies on 
pain variation across different regions. Nevertheless, our 
results may aid the determination of appropriate local 
anesthetic protocols in patients with apex lesions during 
MRI-/TRUS-guided biopsy.
The present study has some limitations that should be 
acknowledged. First, a retrospective design was used, and 
the study was conducted at a single center; therefore, the 
results are sensitive to selection bias. Second, the apex 
PNB was more painful than the base PNB, and may have 
adverse events. The results may also have been affected 
by different total doses of lidocaine injection. We are cur-
rently in the process of conducting a prospective, well-
controlled, randomized multicenter trial to confirm the 
results of this study.
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Conclusions
Prostate cancer is one of the most prevalent cancers, with 
rapidly increasing incidence worldwide. TRUS-guided 
random prostate biopsy is a painful procedure and 
requires appropriate local anesthesia. The results of this 
study indicated that core biopsy of the apex site was more 
painful than was the base site in patients who received 
the base-only PNB. The administration of an additional 
apex PNB provided better overall pain control.
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